Cardiff Oncology (CRDF) Cash from Financing Activities (2011 - 2025)

Cardiff Oncology has reported Cash from Financing Activities for 14 years, with the latest figure at $2.6 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 94.22% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 million (down 95.2% YoY) and the FY2025 annual result came in at $2.6 million, down 95.2% from the prior year.
• Cash from Financing Activities rose to $2.6 million in Q4 2025 per CRDF's latest filing, from $25000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $44.2 million in Q4 2024 and troughed at $3000.0 in Q1 2025.
• A 4-year average of $8.4 million and a median of $2.1 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2021 and 2025: Cash from Financing Activities retreated 15.57% in 2021, then plunged 99.66% in 2025.
• Over 4 years, Cash from Financing Activities stood at $15.0 million in 2021, then tumbled by 99.5% to $75000.0 in 2022, then soared by 58817.33% to $44.2 million in 2024, then tumbled by 94.22% to $2.6 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.6 million, $25000.0, and $3000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.